HC
SION

Hurley Capital’s Sionna Therapeutics SION Stock Holding History

Hurley Capital’s Portfolio SION Stock Details SION Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.97K Buy
+113
New +$4.52K ﹤0.01% 437

Other funds holding SION

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Hurley Capital's SION Position: Q2 2026 in Review

Hurley Capital opened a new position in Sionna Therapeutics (SION) in Q2 2026: 113 shares worth $4.97K. The stake represents ﹤0.01% of the portfolio and ranks #437 among its holdings.

147 funds tracked by Wall St. Rank hold SION as of Q2 2026.

  • Hurley Capital held 113 shares of Sionna Therapeutics worth $4.97K as of Q2 2026.
  • Sionna Therapeutics was a new Hurley Capital position in Q2 2026.
  • Sionna Therapeutics made up ﹤0.01% of Hurley Capital's portfolio in Q2 2026, its #437 holding.
  • 147 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q2 2026.

Based on Hurley Capital's 13F filing for Q2 2026, filed 10 Aug 2026.